GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BeiGene Ltd (STU:49B) » Definitions » Inventories, Finished Goods

BeiGene (STU:49B) Inventories, Finished Goods : €252 Mil (As of Dec. 2024)


View and export this data going back to 2018. Start your Free Trial

What is BeiGene Inventories, Finished Goods?

BeiGene's quarterly finished goods declined from Jun. 2024 (€223 Mil) to Sep. 2024 (€200 Mil) but then increased from Sep. 2024 (€200 Mil) to Dec. 2024 (€252 Mil).

BeiGene's annual finished goods increased from Dec. 2022 (€163 Mil) to Dec. 2023 (€209 Mil) and increased from Dec. 2023 (€209 Mil) to Dec. 2024 (€252 Mil).


BeiGene Inventories, Finished Goods Historical Data

The historical data trend for BeiGene's Inventories, Finished Goods can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BeiGene Inventories, Finished Goods Chart

BeiGene Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Inventories, Finished Goods
Get a 7-Day Free Trial Premium Member Only Premium Member Only 56.38 137.25 162.84 209.31 252.39

BeiGene Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Inventories, Finished Goods Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 209.31 221.03 223.06 200.38 252.39

BeiGene Inventories, Finished Goods Calculation

The products in a manufacturer's inventory that are completed and are waiting to be sold.


BeiGene Business Description

Industry
Address
c/o Mourant Governance Services (Cayman) Limited, 94 Solaris Avenue, Camana Bay, Grand Cayman, CYM, KY1-1108
Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeiGene is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeiGene runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeiGene's revenue.

BeiGene Headlines

No Headlines